PR Newswire Clinical TrialsOriginal article
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
Phase 2ibezapolstatPositive
AI Analysis
Summary
Acurx Pharmaceuticals has enrolled the first patient in the PATHFINDER Phase 2 clinical trial of ibezapolstat for multiply-recurrent C. difficile infection. The trial is designed to support a planned Phase 3 ASPIRE trial in the broader acute CDI patient population.
Clinical Trial Data
Phase
2
Outcome Details
First patient enrolled in PATHFINDER Phase 2 trial
Importance:5/10
Sentiment:
0.50
Phase 2CDIClinical trial initiationRare disease
Read the original article
Published by PR Newswire Clinical Trials on September 29, 2026 12:01 PM